SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LEGN

Legend Biotech Corp (NASDAQ:LEGN)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$15.25-$0.85 (-5.28%)
 
Market cap
$2.82B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 5, 2020
Market Cap$2.82B-43.8%
Revenue (ttm)$1.36B+49.5%
Net Income-$215.00K+99.9%
EPS$0.00+97.7%
Shares Out184.94M
PE Ration/a
Forward PE31.29
Dividendn/a
Ex-Dividend Daten/a
Volume3,422,884
Open$15.95
Previous Close$16.10
Day's Range$15.14 - $16.11
52-Week Range$15.14 - $37.50
Beta0.40
AnalystsBuy
Price Target$61.00(+300.00%)
Earnings DateMar 9, 2027

About LEGN

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Address
2101 Cottontail Lane, Somerset, NJ, 08873, US
Market Cap
2.82 billion
Employees
3,300
Industrial Classification
Biotechnology

Legend Biotech Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
74th Percentile Overall Score
LEGN InsiderScore:84 / 99

Legend Biotech Corp scored higher than 74% of companies evaluated by InsiderBuying, and ranked 25th out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Legend Biotech Corp bought $183.3K of stock across 2 purchases in the last 90 days, the largest of them $93.8K.

Stake Increase

The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$566.75K
Bought
$346.45K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy2 Hold0 SellAvg target $53.43 (+250.4%)

6 firms rating LEGN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From LEGN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.28%
5 Days
-12.15%
1 Month
-19.31%
6 Months
-48.08%
1 Year
-43.83%

$LEGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LEGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LEGN's directors and management

Net Shares Purchased by Insiders−40k−20k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LEGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LEGN Revenue by Segment or Geography

LEGN's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New LEGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LEGN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LEGN

IBBiShares Biotechnology ETF$19.38M
IEMGiShares Core MSCI Emerging Markets ETF$12.74M
PBEInvesco Biotechnology & Genome ETF$9.01M
CANCTema Oncology ETF$3.19M
GNOMGlobal X - Genomics & Biotechnology ETF$2.91M
EEMiShares MSCI Emerging Markets ETF$2.83M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from LEGN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
88.74
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
58

News check: Q3 earnings showed revenue growth and profitability swing, but RBC cut price target despite maintaining outperform; concerns over decelerating CARVYKTI demand offset positive sales growth.

Recent Insider Activity

Buys
3
Sells
5
Buy Value
$346.45K
Distinct Buyers
2

Insider Score Trend Over Time

+88.7 since Sep 24
0255075100Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 31.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Nov 17 — Insider Score 86.0Nov 18 — Insider Score 84.5Nov 19 — Insider Score 83.3Nov 20 — Insider Score 82.2Nov 21 — Insider Score 88.6Nov 22 — Insider Score 88.7Sep 24Oct 2Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.20%
PBEInvesco Biotechnology & Genome ETF2.46%
MEMSMatthews Emerging Markets Discovery Active ETF MEMS2.38%
GNOMGlobal X - Genomics & Biotechnology ETF2.22%
CHNALoncar China BioPharma ETF2.06%
CANCTema Oncology ETF1.73%
EMSFMatthews Emerging Markets Sustainable Future Active ETF EMSF1.61%
MEDIHarbor Health Care ETF (MEDI)1.09%
KUREKraneShares MSCI All China Health Care Index ETF0.82%
BBPVirtus Biotech ETF0.70%
JDOCJPMorgan Healthcare Leaders ETF0.30%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.29%

Weight is the stock’s share of each fund’s holdings.